SIGY
Sigyn Therapeutics, Inc.1.7100
-0.1900-10%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.75MP/E (TTM)
-Basic EPS (TTM)
-1.93Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Sigyn Therapeutics posted Q3 FY2025 operating loss of $386.5K, down 52% y/y from $808.5K, while nine-month loss hit $1.4M versus $2.0M prior year; net loss swelled to $578.5K from $1.2M y/y due to $846K preferred share inducement and debt costs exceeding cuts in R&D and G&A. Cash burn eased to $646K YTD from $582K, ending at $85.6K after $720K note proceeds, yet stockholders' deficit deepened to $5.9M amid $2.5M net convertible notes and $181K derivative liability. Debt rolled over smoothly. Cash won't last.
10-Q
Q2 FY2025 results
Sigyn Therapeutics posted a Q2 net loss of $1.5M, up from $862K last year, while YTD loss widened to $2.1M from $1.6M amid zero revenue and a 17.6% drop in operating expenses to $1.0M, driven by slashed R&D spending. Cash dwindled to $459 from $12K at year-end, with operating cash burn at $447K offset by $435K in convertible note proceeds; free cash flow not disclosed in the 10-Q. Convertible debt swelled to $2.3M net, mostly short-term at rates up to 273%, while the office lease ended in May, trimming liabilities. EPS held steady at -$0.90 quarterly on 1.6M shares, with anti-dilutive effects from 2M potential shares flagged. Yet cash is nearly gone. Board and CSO quit in August over lapsed D&O insurance, spotlighting governance risks.
8-K
Funding secured, board resigns
Sigyn Therapeutics secured up to $550,000 in one-year 8% convertible notes from Lambda Venture Partners on August 8, 2025, issuing an initial $110,000 tranche for $100,000 net proceeds after fees. Yet three board members resigned effective August 7-8, 2025, due to the lapse of D&O insurance on August 4, with no replacement yet. This funding bolsters working capital amid governance shakeup.
10-Q
Q1 FY2025 results
Sigyn Therapeutics posted a narrower Q1 FY2025 net loss of $668,564, down 11.8% y/y from $758,088, as operating expenses fell 13.3% to $546,059 on slashed R&D outlays while compensation rose. No revenue yet, but cash burn eased slightly to $294,446 from operations, offset by $295,197 in fresh convertible note proceeds, leaving $12,895 in cash against $5.2M liabilities, including $2.2M net convertibles (up 15.8% q/q, derived) and $213K promissory notes—defaults on $485K notes loom amid restructuring talks. EPS improved to $(0.42) from $(0.62), matching 1.6M diluted shares with no anti-dilution flags. Lease terminated in May 2025 for $32.7K payout. Yet competition from better-resourced rivals shadows clinical progress.
10-K
FY2024 results
Sigyn Therapeutics posted a net loss of $3.3 million for FY2024 ended December 31, 2024, an improvement from $4.1 million in 2023, driven by lower interest expenses on convertible debt amid ongoing pre-revenue development of blood purification devices. Operating expenses rose modestly 2.6% to $2.5 million, with R&D steady at $773K while investor relations costs jumped to support brand awareness; no quarterly breakdowns disclosed, but annual cash burn eased to $872K from $1.4 million, fueled by $873K in financing inflows. Liquidity remains precarious with $12K cash against $4.7 million liabilities, including $2.1 million in notes now in default and pending restructurings. No guidance issued. Regulatory delays could stall quarterly progress.
IPO
Employees
Sector
Industry
CALC
CalciMedica, Inc.
5.22+0.59
CTSO
Cytosorbents Corporation
0.64+0.01
CYDY
CytoDyn Inc.
0.32+0.02
DSGN
Design Therapeutics, Inc.
9.62+0.50
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SIGA
SIGA Technologies Inc.
6.28-0.04
SLXN
Silexion Therapeutics Corp
2.61+0.05
SYBX
Synlogic, Inc.
1.06+0.01
TOVX
Theriva Biologics, Inc.
0.21+0.01
VIR
Vir Biotechnology, Inc.
6.48-0.24